BARRETT THORNHILL
BARRETT THORNHILL is named as a lobbyist in 21 lobbying reports we hold, filed by 1 registrant for 21 clients.
Earlier government jobs, as reported
A lobbying report lists each lobbyist's covered positions: jobs in Congress or the executive branch that the law asks a lobbyist to disclose. Each line is copied as a report states it.
No report we hold lists a covered position for BARRETT THORNHILL.
Registrants and clients
- FORBES-TATE · 21 reports
Clients: AMGEN USA, INC.; ASSOCIATION OF AMERICAN MEDICAL COLLEGES; BIO-RAD LABORATORIES; CAI INVESTMENTS; CLARITEV (FKA MULTIPLAN CORPORATION); GENENTECH; GILEAD SCIENCES, INC.; GLOBAL MEDICAL RESPONSE; HALOZYME THERAPEUTICS, INC.; INVIVYD; IONIS PHARMACEUTICAL, INC.; MERCK KGAA DARMSTADT GERMANY; NOVARTIS, INC.; PHRMA; SYDNEXIS; TARSUS PHARMACEUTICALS; TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION; THE CURE COALITION; ULTRAGENYX PHARMACEUTICAL; VIR BIOTECHNOLOGY, INC.; YTY.
Bills named where this lobbyist is listed, and how the House and the Senate voted
4 bills named in these reports. None of them became law in our record, so no recorded vote is shown. A lobbying report names the houses of Congress and the agencies the lobbyists contacted. It does not say which members or staff they met.
| Bill | Status | How the House and the Senate voted |
|---|---|---|
| H.R. 1672Maintaining Investments in New Innovation Act | Introduced | No recorded vote in our record |
| H.R. 3037Access to Breast Cancer Diagnosis Act of 2025 | Introduced | No recorded vote in our record |
| S. 832EPIC Act of 2025 | Introduced | No recorded vote in our record |
| S. 1500Access to Breast Cancer Diagnosis Act of 2025 | Introduced | No recorded vote in our record |
Issues named: Health Issues (18), Medicare/Medicaid (11), Budget/Appropriations (5), Manufacturing (4), Trade (domestic/foreign) (4), Taxation/Internal Revenue Code (3), Chemicals/Chemical Industry (2), Consumer Issues/Safety/Products (2), Copyright/Patent/Trademark (2), Medical/Disease Research/Clinical Labs (2), Defense (1), Disaster Planning/Emergencies (1), and 3 mores.
Every report
| Client | Registrant | Kind, as filed | Posted | Report |
|---|---|---|---|---|
| BIO-RAD LABORATORIESHealth Issues, Defense, Medicare/Medicaid | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| ASSOCIATION OF AMERICAN MEDICAL COLLEGESEducation, Health Issues, Medicare/Medicaid | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| IONIS PHARMACEUTICAL, INC.Health Issues, Medicare/Medicaid | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| AMGEN USA, INC.Taxation/Internal Revenue Code, Medicare/Medicaid, Medical/Disease Research/Clinical Labs, Budget/Appropriations | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| INVIVYDHealth Issues | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| THE CURE COALITIONBudget/Appropriations, Health Issues | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATIONHealth Issues | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| TARSUS PHARMACEUTICALSHealth Issues | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| SYDNEXISHealth Issues | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| HALOZYME THERAPEUTICS, INC.Medicare/Medicaid, Health Issues | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| VIR BIOTECHNOLOGY, INC.Health Issues | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| GLOBAL MEDICAL RESPONSEHealth Issues, Medicare/Medicaid, Disaster Planning/Emergencies | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| GILEAD SCIENCES, INC.Health Issues | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| YTYManufacturing | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| ULTRAGENYX PHARMACEUTICALHealth Issues | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| CAI INVESTMENTSBudget/Appropriations, Chemicals/Chemical Industry, Consumer Issues/Safety/Products, Health Issues, Manufacturing, Medical/Disease Research/Clinical Labs | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| MERCK KGAA DARMSTADT GERMANYChemicals/Chemical Industry, Trade (domestic/foreign), Manufacturing | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| PHRMAPharmacy, Consumer Issues/Safety/Products, Trade (domestic/foreign), Health Issues, Medicare/Medicaid | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| NOVARTIS, INC.Health Issues, Medicare/Medicaid, Trade (domestic/foreign), Budget/Appropriations, Copyright/Patent/Trademark, Taxation/Internal Revenue Code | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| GENENTECHCopyright/Patent/Trademark, Manufacturing, Budget/Appropriations, Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code | FORBES-TATE | 2nd Quarter - Report | The report on LDA.gov | |
| CLARITEV (FKA MULTIPLAN CORPORATION)Medicare/Medicaid, Labor Issues/Antitrust/Workplace, Health Issues | FORBES-TATE | 2nd Quarter - Termination | The report on LDA.gov |
Campaign gifts this lobbyist reported
Lobbyists and registrants report their political contributions twice a year (form LD-203). We hold these reports only for contributions to the campaign committees of members who sponsored or cosponsored a bill named in a lobbying report. Any other contribution: Not checked yet.
No contribution report we hold lists a gift from this filer.
Where this comes from
Lobbying Disclosure Act reports (LD-2), LDA.gov. We save our own copy of each page of LDA.gov's list of reports before we read it. These pages were built from our copies on .
2026-Q2: every page of LDA.gov's list saved and read.
A lobbying report states the registrant's income from the client (a lobbying firm) or its own lobbying expenses (an organization lobbying for itself), for the whole quarter and every issue together. A report of less than $5,000, or of no lobbying activity, states no figure. It is not the amount spent on one bill.
Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.